BridgeBio Pharma, Inc.
US ˙ NasdaqGS ˙ US10806X1028

SecurityBBIO / BridgeBio Pharma, Inc.
InstitutionComerica Bank
Latest Disclosed Ownership52,480 shares
Latest Disclosed Value $ 4,014,206
Comerica Bank reports 10.73% increase in ownership of BBIO / BridgeBio Pharma, Inc.

On January 29, 2026 - Comerica Bank filed a 13F-HR form disclosing ownership of 52,480 shares of BridgeBio Pharma, Inc. (US:BBIO) valued at $4,014,195 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 14, 2025 disclosing 47,396 shares of BridgeBio Pharma, Inc.. This represents a change in shares of 10.73% during the quarter. The current value of the position is $3,533,478 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F BRIDGEBIO PHARMA COM 10806X102 52,480 5,084 10.73 4,014 63.10 0.0160
2025-11-14 2025-09-30 13F BRIDGEBIO PHARMA COM 10806X102 47,396 12,367 35.31 2,462 62.76 0.0093
2025-08-14 2025-06-30 13F BRIDGEBIO PHARMA COM 10806X102 35,029 -48,662 -58.14 1,513 -47.74 0.0059
2025-05-14 2025-03-31 13F BRIDGEBIO PHARMA COM 10806X102 83,691 -22,425 -21.13 2,893 -0.62 0.0122
2025-02-14 2024-12-31 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 106,116 60,256 131.39 2,912 149.44 0.0117
2025-02-14 2024-12-31 13F BRIDGEBIO PHARMA COM 10806X102 106,116 60,256 2,912 0.0098
2024-11-14 2024-09-30 13F BRIDGEBIO PHARMA COM 10806X102 45,860 33,065 258.42 1,168 260.19 0.0046
2024-08-15 2024-06-30 13F BRIDGEBIO PHARMA COMMON 10806X102 12,795 -25,719 -66.78 324 -72.77 0.0013
2024-05-16 2024-03-31 13F BRIDGEBIO PHARMA COMMON 10806X102 38,514 38,277 16,150.63 1,191 13,122.22 0.0051
2024-02-14 2023-12-31 13F BRIDGEBIO PHARMA COMMON 10806X102 237 -109 -31.50 10 0.00 0.0000
2023-11-21 2023-09-30 13F BRIDGEBIO PHARMA COMMON 10806X102 346 346 9 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.